Acute Lymphoblastic Leukemia

Comprehensive care for ALL, including intensive chemotherapy, targeted therapy, and stem cell transplantation.

Back to All Treatments
Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Hematologic Malignancies

Overview

Comprehensive care for ALL, including intensive chemotherapy, targeted therapy, and stem cell transplantation.

When to Consult

Upon diagnosis of ALL or suspicious blood test results.

What to Bring

CBC, peripheral smear, bone marrow biopsy, cytogenetic and molecular test reports.

Risk Factors

Age (more common in children and older adults)
Previous chemotherapy or radiation
Genetic syndromes (Down syndrome)
Family history
Exposure to radiation
Certain genetic mutations
Environmental factors
Immune system disorders

Causes

Genetic mutations in bone marrow cells
Abnormal lymphocyte development
Environmental toxins
Radiation exposure
Genetic predisposition
Viral infections (rare)
Bone marrow cell abnormalities
Complex genetic factors

Treatment Options

Induction Chemotherapy

Intensive initial chemotherapy to achieve complete remission by destroying leukemia cells in bone marrow and blood. Multi-drug regimens including vincristine, prednisone, asparaginase, and anthracyclines administered over 4-6 weeks.

Consolidation Therapy

Post-remission intensive chemotherapy to eliminate any remaining leukemia cells and prevent relapse. High-dose methotrexate, cytarabine, and other agents given in cycles over several months.

Maintenance Therapy

Long-term lower-dose chemotherapy (typically 2-3 years) to prevent recurrence. Includes daily 6-mercaptopurine, weekly methotrexate, and periodic vincristine/prednisone pulses. Essential for sustained remission.

Stem Cell Transplantation

Allogeneic or autologous stem cell transplant for high-risk patients or those who relapse. Replaces diseased bone marrow with healthy stem cells after high-dose chemotherapy. Offers potential cure for selected patients.

Targeted Therapy

Precision treatments including imatinib, dasatinib for Philadelphia chromosome-positive ALL, blinatumomab (bispecific T-cell engager), and inotuzumab ozogamicin for relapsed/refractory disease based on genetic markers.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell therapy, a form of immunotherapy where patient's T cells are genetically modified to attack leukemia cells. Highly effective for relapsed/refractory B-cell ALL, particularly in children and young adults.

Need Treatment?

Schedule a consultation to discuss treatment options for Acute Lymphoblastic Leukemia.